EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry

Aydin Huseynov, Michael Behnes, Holger Nef, Thomas Riemer, Steffen Schneider, Thomas Pfannebecker, Stephan Achenbach, Julinda Mehilli, Thomas Münzel, Tommaso Gori, Jochen Wöhrle, Ralf Zahn und 5 weitere

Clinical Research in Cardiology · 2025

DOI: 10.1007/s00392-025-02707-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Aydin Huseynov und 16 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-U…. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Artery Disease, Drug-Eluting Stents, Off-Label Use. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Vascular, Medizinische Fakultät Mannheim der Universität Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The potential benefits of bioabsorbable stents can be better assessed over the long term. The implantation of bioresorbable scaffold (BRS) in situations with off-label indications provides real-world insights into how clinical events differ in contrast to standard proved indications.

Objectives

The study provides long-term follow-up data about the use of bioresorbable scaffold (BRS) for off-label compared with approved indications.

Methods

Five-year outcome data of an everolimus-eluting, poly-L-lactic acid–based bioresorbable scaffold system (ABSORB, Abbott Vascular, Santa Clara, CA, USA) were evaluated in the prospective, non-interventional, multicenter real-world German-Austrian ABSORB-RegIstRy (GABI-R). The patients were enrolled from a total of 93 centers. Data processing and prospective follow-up were conducted centrally and independently of industry.

Results

A total of 3082 patients were enrolled between 2013 and 2016. Most patients were included into the off-label group (2317, 75.2%). ST-elevation myocardial infarction (STEMI) was significantly more common in the off-label group (35.9% vs. 27.8%, p = 0.003), and the extent of coronary heart disease was higher in the off-label group (coronary 3 vessel disease 28.4% vs. 22.4%, p < 0.001). Patients with off-label indications had statistically significant higher rates of stent thrombosis after 30 days (1.08% vs. 0.26%, p = 0.04) and target vessel failure (TVF) after 6 months (4.62% vs. 2.61%, p = 0.02).

Conclusions

The off-label use of BRS is associated with a higher rate of stent thrombosis in the short term and in the long term with higher MACE events considering more complex lesions and a higher morbidity. In the long term, there are no differences regarding stent thrombosis. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Absorbable ImplantsCoronary Artery DiseaseDrug-Eluting StentsOff-Label UsePercutaneous Coronary InterventionRegistriesAgedFemaleHumansMaleMiddle AgedCoronary AngiographyEverolimusFollow-Up StudiesGermanyProspective StudiesProsthesis DesignTime FactorsTreatment Outcome

Stichwörter der Autor:innen

5-year follow-upBioresorbable scaffoldCoronary artery diseaseOff-label use

Substanzen

Everolimus

Autor:innen und Institutionen

  • First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. a.n.huseynov@gmail.com.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany. a.n.huseynov@gmail.com.
  • First Department of Medicine-Cardiology, Faculty of Medicine Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
  • Heart Centre Segebereger Kliniken GmbH, Bad Segeberg, Germany.
  • Department of Cardiology, University of Giessen, Giessen, Germany.

Förderung

  • Abbott Vascular
  • Medizinische Fakultät Mannheim der Universität Heidelberg

Zitieren

APA

Huseynov, A., Behnes, M., Nef, H., Riemer, T., Schneider, S., Pfannebecker, T., Achenbach, S., Mehilli, J., Münzel, T., Gori, T., Wöhrle, J., Zahn, R., Kastner, J., Schmermund, A., Richardt, G., Hamm, C. W., & Akin, I. (2025). Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02707-3

Vancouver

Huseynov A, Behnes M, Nef H, Riemer T, Schneider S, Pfannebecker T, et al. Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02707-3

BibTeX
@article{Huseynov2025,
  author = {Huseynov, Aydin and Behnes, Michael and Nef, Holger and Riemer, Thomas and Schneider, Steffen and Pfannebecker, Thomas and Achenbach, Stephan and Mehilli, Julinda and Münzel, Thomas and Gori, Tommaso and Wöhrle, Jochen and Zahn, Ralf and Kastner, Johannes and Schmermund, Axel and Richardt, Gert and Hamm, Christian W and Akin, Ibrahim},
  title = {Absorb® bioresorbable scaffold in “established” versus “off-label” coronary lesions: 5-year data from the GABI-R® registry},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  doi = {10.1007/s00392-025-02707-3}
}
Kostenlos starten →